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Abstract 5 
Background 6 
Low vitamin B12 and folate levels in community-dwelling older people are usually corrected 7 
with supplements. However, the effect of this supplementation on haematological parameters 8 
in older persons is not known. Therefore, we executed a systematic review and individual 9 
participant data meta-analysis of randomized placebo-controlled trials (RCTs). 10 
Methods 11 
We performed a systematic search in PubMed, EMBASE, Web of Science, Cochrane and 12 
CENTRAL for RCTs published between January 1950 and April 2016 where community-13 
dwelling elderly (60+ years) who were treated with vitamin B12 or folic acid or placebo. The 14 
presence of anaemia was not required. We analysed the data on haematological parameters 15 
with a 2-stage IPD meta-analysis. 16 
Results 17 
We found 494 full papers covering 14 studies. Data were shared by the authors of four RCTs 18 
comparing vitamin B12 with placebo (n=343) and of three RCTs comparing folic acid with 19 
placebo (n=929). We found no effect of vitamin B12 supplementation on haemoglobin 20 
(change 0.00 g/dL, 95% CI -0.19;0.18), and no effect of folic acid supplementation (change -21 
0.09 g/dL, 95% CI -0.19;0.01). The effects of supplementation on other haematological 22 
parameters were similar. The effects did not differ by sex or by age group. Also, no effect 23 
was found in a subgroup of patients with anaemia and a subgroup of patients who were 24 
treated >4 weeks. 25 
Conclusions 26 
Evidence on the effects of supplementation of low concentrations of vitamin B12 and folate 27 
on haematological parameters in community-dwelling older people is inconclusive. Further 28 
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research is needed before firm recommendations can be made concerning the 29 
supplementation of vitamin B12 and folate. 30 
  31 
6 
 
Background 32 
The prevalence of anaemia in older persons is high (around 10% among people aged 33 
≥65 years) and rises with advancing age (1, 2). In about one third of older persons with 34 
anaemia co-incidental nutritional deficiencies, such as iron, vitamin B12 and folate 35 
deficiency, exist [(2). Among people aged ≥75 years, the prevalence of both vitamin B12 and 36 
folate deficiency is >10% (3-7).These deficiencies are not only associated with macrocytic 37 
anaemia but also with dementia, peripheral neuropathy, combined degeneration of the spinal 38 
cord and cardiovascular disease (8-11).  39 
As the prevalence of deficiencies in vitamin B12 and folate are high, screening for 40 
deficiencies in vitamin B12 and folate has been recommended as part of a geriatric work-up 41 
(12, 13). Guidelines recommend vitamin B12 supplementation in patients with very low 42 
serum vitamin B12 concentrations due to lack of intrinsic factor (IF) (pernicious anaemia) or 43 
food-vitamin B12 malabsorption. Several studies have shown significant increases in 44 
haemoglobin after vitamin B12 administration in these patients (14-16). Thus, when low 45 
levels of vitamin B12 and folate are found, patients are often treated with injections or oral 46 
supplements (9, 11, 17). 47 
 Interestingly, evidence of an association between a low serum vitamin B12 48 
concentration and anaemia in older individuals in the general population is limited and 49 
inconclusive. Data from the Leiden 85-plus Study showed that low vitamin B12 50 
concentrations (<150 pmol/L) in 85-year-old persons are not associated with anaemia (18). 51 
Also, the effect of vitamin B12 supplementation on haemoglobin and Mean Corpuscular 52 
Volume (MCV) in elderly with low levels of vitamin B12 is unclear (19). 53 
In contrast to vitamin B12 deficiency, folate deficiency seems to be associated with 54 
the presence and the development of anaemia in older individuals (18). Therefore, early 55 
detection of folate deficiency may identify older individuals at risk of anaemia. Preventive 56 
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folic acid supplementation or folic acid fortification of grain and cereal products has been 57 
recommended and has already been initiated at population level in several countries. 58 
However, to date, it is not known if older persons benefit from of prophylactic folic acid 59 
supplementation with regards to haemoglobin levels, as no evidence is available to support 60 
this assumption. 61 
In order to evaluate the effect of vitamin B12 and folic acid supplementation on 62 
haematological parameters in elderly, we executed a systematic review and individual 63 
participant data meta-analysis of randomized placebo-controlled trials. 64 
 65 
Methods 66 
Criteria for considering studies for this meta-analysis 67 
We considered all randomized controlled trials (RCTs) where community-dwelling elderly 68 
(60+ years) were treated with vitamin B12 or folic acid (all dosages and all forms of 69 
administration) and were compared with elderly who were given a placebo. The presence of 70 
anaemia or a vitamin B12/folate deficiency was not required for inclusion. Exclusion criteria 71 
were: mean or median age less than 60 years, no availability of haemoglobin concentrations 72 
or haematocrit at baseline and during follow-up, combinations of vitamin B12 and folic acid 73 
supplementation, and specific populations (e.g. studies in diabetes patients or patients with 74 
renal failure). 75 
Search strategy 76 
We performed a search on PubMed, EMBASE, Web of Science, Cochrane and CENTRAL 77 
with relevant MeSH-headings and title words for vitamin B12 and folic acid for randomized 78 
controlled trials (RCTs) published between January 1950 and April 2016. Case reports and 79 
letters were excluded. We also searched ClinicalTrials.gov for (ongoing) trials on vitamin 80 
B12 or folic acid supplementation in older persons. We also used backward and forward 81 
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citation screening. The electronic search was performed by an information scientist from the 82 
Walaeus Library of the Leiden University Medical Center. The exact search strategy can be 83 
found in Supplementary file 1. 84 
Selection of studies 85 
All titles and abstracts found in the electronic databases were assessed by the last author. Full 86 
copies were acquired of articles that were potentially relevant or in case of uncertainty. WPJ 87 
den Elzen and LW Bermingham appraised these full copies. Disagreement was resolved by 88 
consensus. Investigators from each eligible study were invited to join the project and to share 89 
their data. The risk of bias of the included studies was assessed using the Cochrane risk of 90 
bias assessment table (see Supplemental File 3). 91 
Data collection 92 
We centrally collected data on demographic characteristics, pre- and post-treatment 93 
concentrations of serum vitamin B12, serum / red cell folate, homocysteine, methylmalonic 94 
acid, haemoglobin, as well as on levels of haematocrit, Mean Corpuscular Volume (MCV) 95 
and Red Blood Cell Count (RBC) for all individuals included in the studies. Since vitamin 96 
B12 and folate deficiency is defined ideally in terms of serum values of vitamin B12 and 97 
folate in combination with homocysteine and methylmalonic acid (8) we also collected data 98 
on homocysteine and methylmalonic acid, when available.  99 
Analyses 100 
We combined the results of the individual studies into two meta-analyses; one on the effect of 101 
vitamin B12 supplementation and one on the effect of folic acid supplementation on 102 
haematological parameters. We performed a two-stage individual participant data meta-103 
analysis. First, for all individual studies separately, we calculated the mean change in 104 
haematological parameters between baseline and follow-up (i.e. follow-up minus baseline) in 105 
the active treatment group, and in the placebo group (IBM SPSS Statistics 20). Subsequently, 106 
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we calculated the difference in mean change (together with its standard error) between the 107 
active treatment group and placebo group. Then, pooled estimates for each outcome were 108 
calculated using a fixed-effects model, using Review Manager version 5.3.3 The Nordic 109 
Cochrane Centre, The Cochrane Collaboration, 2014. We measured statistical heterogeneity 110 
using the I2 statistic. An I2 value greater than 50% indicates at least moderate statistical 111 
heterogeneity (20). 112 
We performed subgroup analyses for sex and age. Interaction between treatment and sex, and 113 
treatment and age, was evaluated by linear regression analysis. Further post-hoc analyses 114 
were performed in the subgroup of participants with anaemia at baseline, in MCV subgroups, 115 
and in studies with a short (≤4 weeks) versus long duration of treatment (>4 weeks). 116 
 117 
Results 118 
Selection of studies 119 
The electronic search identified 5691 potentially relevant titles and abstracts of papers 120 
(performed 25-3-2016). We identified 494 papers, of which 47 fulfilled our inclusion criteria 121 
(Figure 1). Investigators from these studies were invited to join the project and to share their 122 
data. Eight authors could not provide haematological data because these were not measured 123 
or because individual data were not available anymore. Seven authors did not respond to our 124 
request (21-27). The authors of the other 32 papers (n=10 for vitamin B12 and n=22 for folic 125 
acid) agreed to participate in this project and to share their data on haemoglobin 126 
concentrations or haematocrit fractions after supplementation. These 32 papers comprised 4 127 
unique studies on vitamin B12 supplementation (28-31) and 3 unique studies on folic acid 128 
supplementation (Table 1) (32-34). No additional (ongoing) studies were found on 129 
ClinicalTrials.gov. The risk of bias of included studies was low (see Supplemental File 1). 130 
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Table 1 describes a summary of the characteristics of the included studies. The sample sizes 131 
of the included studies varied from ‘n=24’ (33) to ‘n=802’(32). Also, the dosage and the 132 
forms of administration and the time to follow-up varied to a great extent (Table 1).  133 
Heterogeneity 134 
We found no indications for statistical heterogeneity in the studies on vitamin B12 (I2=0%) 135 
for all 4 outcomes, but for the studies on folic acid we found indications for at least moderate 136 
statistical heterogeneity (I2=72%) when analysing RBC as an outcome. Also, clinical 137 
heterogeneity existed between studies due to different methods of administration, dosage of 138 
vitamin B12 and folic acid, outcomes and follow-up time. Therefore, we show both the 139 
results of the individual studies and the results of the pooled effect estimates (Table 2).  140 
Results of analyses 141 
In table 2 we show the baseline values of haemoglobin, vitamin B12 and folate. The numbers 142 
of individuals with anaemia was relatively small. None of the individual studies showed a 143 
significant effect of vitamin B12 (total n=343) or folic acid supplementation (total n=929) on 144 
changes in haematological parameters, except for the study by Ntaios on RBC (Table 3). The 145 
pooled estimate of the effect on haemoglobin was 0.00 g/dL (95% CI -0.19;0.18) for vitamin 146 
B12 supplementation and -0.09 g/dL (95% CI -0.19;0.01) for folic acid supplementation, 147 
meaning that there was no difference in the mean change in haemoglobin concentrations 148 
during follow-up between vitamin B12 and placebo, and folic acid and placebo.  149 
In addition, no differences in the mean change in other haematological parameters were 150 
observed. For vitamin B12 supplementation, the pooled estimate of the effect was 0.00 g/dL 151 
(95% CI -0;0.01) for haematocrit, 0.07 g/dL (95% CI -0.58;0.72) for MCV and 0.00 g/dL 152 
(95% CI -0.06;0.06) for RBC. For folic acid supplementation, the pooled estimate of effect 153 
was -0.00 g/dL (95% CI -0.01;0) for haematocrit, -0.37 g/dL (95% CI -0.82;0.08) for MCV 154 
and -0.02 g/dL (95% CI -0.05;0.02) for RBC.  155 
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 156 
Subgroup analyses 157 
In none of the subgroups on sex and age a significant effect of vitamin B12 or folic acid 158 
supplementation on haemoglobin concentrations was found (Table 4). The effect of vitamin 159 
B12 and folic acid on haemoglobin was the same for men and women (Pinteraction=0.577 for 160 
vitamin B12 and Pinteraction=0.545 for folic acid) or between different age groups 161 
(Pinteraction=0.793 for vitamin B12 and Pinteraction=0.836 for folic acid). Similar results were 162 
found when we repeated the analyses for haematocrit, MCV and RBC (data not shown). 163 
Post-hoc analyses 164 
When we repeated the analyses in participants with anaemia, we did not observe differences 165 
in the change in haemoglobin levels between those who were treated with vitamin B12 and 166 
those treated with placebo (table 4). In those treated with folic acid, a significantly larger 167 
decline in haemoglobin levels was observed (table 3). Moreover, when we stratified on MCV 168 
(<80 fL, 80-100 fL, >100 fL), in none of the subgroups we observed an effect of vitamin B12 169 
or folic acid administration on haemoglobin. In addition, no effect on haemoglobin was found 170 
in studies with treatment duration of ≤4 weeks or in studies with a treatment duration of >4 171 
weeks, both with vitamin B12 and folic acid (Table 4). 172 
Results from studies without individual participant data 173 
Of the 7 studies that could not be included because of a lack of response from the authors, 4 174 
studies did not report having measured haemoglobin and/or haematocrit levels. We here 175 
discuss the 3 studies that reported having measured haemoglobin and/or haematocrit levels 176 
but of which we did not retrieve data (see Supplemental File 2).  177 
The first study, by Smidt et al., measured haemoglobin and haematocrit at baseline 178 
(25), but did not report haematological data at follow-up. The second study, by Hughes et al., 179 
measured haemoglobin at baseline and at follow-up (26). In their study, 93 men and 132 180 
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women were given intramuscular hydroxocobalamin (1,000 ug.), twice in the first week and 181 
then at weekly intervals for a further four weeks. During their study, there was a small fall in 182 
haemoglobin level, but the difference between the mean changes in those given B12 and 183 
those given placebo was small and not statistically significant (0.01 ± 0.35 g.). In the third 184 
study by Rampersaud et al. in thirty-three healthy, postmenopausal women aged 60–85 years, 185 
treatment groups received two different folate repletion intakes [ie, ≈200 and ≈400 ug 186 
folate/d] (23). In this study haematocrit values did not change significantly over the 14-week 187 
study period. 188 
 189 
Discussion 190 
In this individual participant data meta-analysis we did not observe any significant 191 
measurable change in routine haematological parameters after treatment with vitamin B12 or 192 
folic acid in older persons with either normal or vitamin B12 or folate concentrations below 193 
the reference range.  194 
There are several possible explanations for the lack of effect. First, some studies 195 
consisted mostly of participants without vitamin B12 or folate deficiency or just below the 196 
cut-off values. As these participants may not have had a true tissue deficiency of vitamin B12 197 
or folate, this may have diluted the effect of supplementation. Second, many of the included 198 
studies mainly consisted of participants without anaemia. Perhaps haemoglobin levels in non-199 
anaemic patients are less likely to increase in response to vitamin B12 or folic acid treatment 200 
than haemoglobin levels in anaemic patients (29). Unfortunately, the low numbers of people 201 
with anaemia refrained us from drawing definite conclusions on the effects of 202 
supplementation in an anaemic population with low vitamin B12 or folate concentrations. 203 
Third, a low vitamin B12 or folate concentration alone may not be the only reason to develop 204 
anaemia, and treatment of these low levels may not be sufficient to raise haemoglobin levels. 205 
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Other genetic or environmental factors may be involved in the onset of anaemia (19). Also, 206 
other causes such as chronic inflammation may play a role in the development of anaemia 207 
(35).  208 
Macrocytic anemia is one of the most well-known consequences of vitamin B12 and 209 
folate deficiency. An elevated Mean Corpuscular Volume (MCV) is often seen as an 210 
indication to test for the presence of vitamin B12 or folate deficiency. However, both the 211 
sensitivity and the specificity of a high MCV for these deficiencies are low (10, 36). In our 212 
study, we did not observe an effect of vitamin B12 and folic administration on the change in 213 
MCV. Also, we did not observe an effect of vitamin B12 or folic acid on haemoglobin in the 214 
MCV subcategories. We have to be cautious in interpreting these results as the groups are 215 
small and the heterogeneity between studies is large. However, these results are in line with 216 
previous analyses in the Leiden 85-plus Study where no relationship was found between 217 
vitamin B12 or folate deficiency and changes in MCV over time (18). 218 
This review has some weaknesses. First, there was substantial clinical heterogeneity 219 
between studies, due to differences in methods of administration, dose of vitamin B12 and 220 
folic acid, outcome measures, treatment follow-up time and sample size, so the results of the 221 
meta-analysis have to be interpreted with caution. However, the fact that the results of the 222 
individual studies point in the same direction is reassuring. Second, in the post-hoc analyses 223 
in the subgroup with anaemia, we observed a significantly larger decline in haemoglobin 224 
levels in those treated with folic acid. This unexpected finding may perhaps be explained by 225 
random error due to multiple testing and the low number of participants this subgroup. Third, 226 
we cannot exclude the possibility of bias as not all studies that were identified in our 227 
systematic search of the literature could be included, because some authors did not respond to 228 
our request or individual participant data were no longer available. However, these studies 229 
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confirm our findings as they also did not observe significant changes in haemoglobin or 230 
haematocrit levels (23, 25, 26).  231 
 232 
Conclusions 233 
We did not observe any significant change in routine haematological parameters after 234 
treatment with vitamin B12 or folic acid in older persons with either normal vitamin B12 or 235 
folate concentrations, or concentrations of vitamin B12 or folate below the reference range. 236 
However, we cannot draw firm conclusions because the amount of studies was low, relatively 237 
few individuals with anaemia could be included, and the clinical heterogeneity between 238 
studies was substantial. Furthermore, we cannot draw conclusions on other benefits of 239 
supplementation of vitamin B12 or folate other than haematological outcomes. 240 
Further well-designed large studies are required to determine whether vitamin B12 241 
and folic acid supplementation are beneficial for older patients with low vitamin B12 or 242 
folate concentrations and anaemia or prophylactic effects of these supplements.  243 
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Figure legends 353 
Figure 1. Schematic representation of the selection of publications for this meta-analysis 354 
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